Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostatic Neoplasms, Castration-Resistant: early-phase trial registry
7 of 11 indexed Prostatic Neoplasms, Castration-Resistant trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 7 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Prostatic Neoplasms, Castration-Resistant: 11 US clinical trials tracked, 7 recruiting.
Prostatic Neoplasms, Castration-Resistant is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 2 of these trials.
Enrollment posture brief
Registry condition prostatic-neoplasms-castration-resistant
OPEN 7 | RECR 64% | LATE 2 | EARLY 7 | RANK #1577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Melanoma (64% recruiting · 22 trials)
Prostatic Neoplasms, Castration-Resistant lists 7 open slots (64% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostatic Neoplasms, Castration-Resistant on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostatic Neoplasms, Castration-Resistant is recruiting above its size-band peers.
7 of 11 indexed trials (63.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Prostatic Neoplasms, Castration-Resistant research.
Janssen Research & Development accounts for 2 of 11 trials (18.2%). 10 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostatic Neoplasms, Castration-Resistant enrolment sits around 136 participants.
Median target enrolment is 136 among the 11 trials that report a genuine target (sentinel values excluded). 4 of those (36.4%) plan for fewer than 100 participants.
-
Prostatic Neoplasms, Castration-Resistant research is mostly interventional.
9 interventional and 2 observational studies make up this index (81.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development
NCT07225946
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis Pharmaceuticals
NCT04104776
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Merck Sharp & Dohme
NCT06353386
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Clarity Pharmaceuticals
NCT04868604
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Celcuity
NCT06190899
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
Weill Medical College of Cornell University
NCT05743621
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
VA Greater Los Angeles Healthcare System
NCT06706921
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development
NCT03431350
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
Pfizer
NCT05520138
Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
Bayer
NCT02899104
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
Boehringer Ingelheim
NCT02204072
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostatic Neoplasms, Castration-Resistant records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostatic Neoplasms, Castration-Resistant trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostatic Neoplasms, Castration-Resistant page
11 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Prostatic Neoplasms, Castration-Resistant trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Janssen Research & Development sponsors the most Prostatic Neoplasms, Castration-Resistant trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostatic Neoplasms, Castration-Resistant condition card totals 11 registered trials; most-linked intervention Enzalutamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.